Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Original Article
  • Published:

Myeloma

Heterogeneity of t(4;14) in multiple myeloma. Long-term follow-up of 100 cases treated with tandem transplantation in IFM99 trials

Leukemia volume 21, pages 2020–2024 (2007)Cite this article

Abstract

One hundred de novo multiple myeloma patients with t(4;14) treated with double intensive therapy according to IFM99 protocols were retrospectively analyzed. The median overall survival (OS) and event-free survival (EFS) were 41.4 and 21 months, respectively, as compared to 65 and 37 for patients included in the IFM99 trials without t(4;14) (P<10−7). We identified a subgroup of patients presenting at diagnosis with both low β2-microglobulin <4 mg/l and high hemoglobin (Hb) ⩾10 g/l (46% of the cases) with a median OS of 54.6 months and a median EFS of 26 months, respectively, which benefits from high-dose therapy (HDT); conversely patients with one or both adverse prognostic factor (high β2-microglobulin and/or low Hb) had a poor outcome. The achievement of either complete response or very good partial response after HDT was also a powerful independent prognostic factor for both OS and EFS.

This is a preview of subscription content, access via your institution

Access options

Buy this article

  • Purchase on Springer Link
  • Instant access to full article PDF
Buy now

Prices may be subject to local taxes which are calculated during checkout

Figure 1
Figure 2
Figure 3
Figure 4
Figure 5
Figure 6

Similar content being viewed by others

References

  1. Bergsagel PL, Kuehl WM . Chromosome translocations in multiple myeloma. Oncogene 2001; 20: 5611–5622.

    Article  CAS  Google Scholar 

  2. Nishida K, Tamura A, Nakazawa N, Ueda Y, Abe T, Matsuda F et al. The Ig heavy chain gene is frequently involved in chromosomal translocations in multiple myeloma and plasma cell leukemia as detected by in situ hybridization. Blood 1997; 90: 526–534.

    CAS  PubMed  Google Scholar 

  3. Avet-Loiseau H, Lai JY, Facon T, Brigaudeau C, Morineau N, Maloisel F et al. High incidence of translocations t(11;14)(q13;q32) and t(4;14)(p16;q32) in patients with plasma cell malignancies. Cancer Res 1998; 58: 5640–5645.

    CAS  PubMed  Google Scholar 

  4. Avet-Loiseau H, Brigaudeau C, Morineau N, Talmant P, Lai JY, Daviet A et al. High incidence of cryptic translocations involving the Ig heavy chain gene in multiple myeloma, as shown by fluorescence in situ hybridisation. Genes Chromos Cancer 1999; 24: 9–15.

    Article  CAS  Google Scholar 

  5. Chesi M, Nardini E, Brents LA, Schrock E, Ried T, Kuehl WM et al. Frequent translocation t(4;14)(p16.3;q32.3) in multiple myeloma is associated with increased expression and activating mutations of fibroblast growth factor receptor 3. Nat Genet 1997; 16: 260–264.

    Article  CAS  Google Scholar 

  6. Chesi M, Nardini E, Lim RS, Smith KD, Kuehl WM, Bergsagel PL . The t(4;14) translocation in myeloma dysregulates both FGFR3 and a novel gene, MMSET, resulting in IgH/MMSET hybrid transcripts. Blood 1998; 92: 3025–3034.

    CAS  PubMed  Google Scholar 

  7. Intini D, Baldini L, Fabris S, Lombardi L, Ciceri G, Maiolo AT et al. Analysis of FGFR3 gene mutations in multiple myeloma patients with t(4;14). Br J Haematol 2001; 114: 362–364.

    Article  CAS  Google Scholar 

  8. Santra M, Zhan F, Tian E, Barlogie B, Shaughnessy J . A subset of multiple myeloma harbouring the t(4;14)(p16;q32) translocation lacks FGFR3 expression but maintains an IGH/MMSET fusion transcript. Blood 2003; 101: 2374–2376.

    Article  CAS  Google Scholar 

  9. Keats JJ, Reiman T, Maxwell CA, Taylor BJ, Larratt LM, Mant MJ et al. In multiple myeloma, t(4;14)(p16;q32) is an adverse prognostic factor irrespective to FGFR3 expression. Blood 2003; 101: 1520–1529.

    Article  CAS  Google Scholar 

  10. Fonseca R, Blood E, Rue M, Harrington D, Oken MM, Kyle RA et al. Clinical and biologic implications of recurrent genomic aberrations in myeloma. Blood 2003; 101: 4569–4575.

    Article  CAS  Google Scholar 

  11. Moreau P, Facon T, Leleu X, Morineau N, Huyghe P, Harousseau JL et al. Recurrent 14q32 translocations determine the prognosis of multiple myeloma, especially in patients receiving intensive chemotherapy. Blood 2002; 100: 1579–1583.

    Article  CAS  Google Scholar 

  12. Jaksic W, Trudel S, Chang H, Trieu Y, Qi X, Mikhaek J et al. Clinical outcomes in t(4;14) multiple myeloma: a chemotherapy-sensitive disease characterized by rapid relapse and alkylating agent resistance. J Clin Oncol 2005; 23: 7069–7073.

    Article  CAS  Google Scholar 

  13. Gertz M, Lacy MQ, Dispenzieri A, Greipp PR, Litzow MR, Henderson KJ et al. Clinical implications of t(11;14)(q13;q32), t(4;14)(p16.3;q32), and –17p13 in myeloma patients treated with high-dose therapy. Blood 2005; 106: 2837–2840.

    Article  CAS  Google Scholar 

  14. Cavo M, Terragna C, Renzulli M, Zamagni E, Tosi P, Testoni N et al. Poor outcome with front-line autologous transplantation in t(4;14) multiple myeloma: low complete remission rate and short duration of remission. J Clin Oncol 2006; 24: e4–e5.

    Article  Google Scholar 

  15. Gutierrez NC, Castellanos MV, Martin ML, Mateos MV, Hernandez JM, Fernandez M et al. Prognostic and biological implications of genetic abnormalities in multiple myeloma undergoing autologous stem cell transplantation: t(4 ;14) is the most relevant adverse prognostic factor, whereas RB deletion as a unique abnormality is not associated with adverse prognosis. Leukemia 2007; 21: 143–150.

    Article  CAS  Google Scholar 

  16. Attal M, Harousseau JL, Leyvraz S, Doyen C, Hulin C, Benboubker L et al. Maintenance treatment with thalidomide after autologous transplantation for myeloma: final analysis of a prospective randomized study of the IFM. Blood 2006; 108: 3289–3294.

    Article  CAS  Google Scholar 

  17. Garban F, Attal M, Michallet M, Hulin C, Bourhis JH, Yakoub-Agha I et al. Prospective comparison of autologous stem cell transplantation followed by a dose-reduced allograft (IFM99-03 trial) with tandem autologous stem cell transplantation (IFM99-04 trial) in high-risk de novo multiple myeloma. Blood 2006; 107: 3474–3480.

    Article  CAS  Google Scholar 

  18. Moreau P, Hulin C, Garban F, Yakoub-Agha I, Benboubker L, Attal M et al. Tandem autologous stem cell transplantation in high-risk de novo multiple myeloma: final results of the prospective and randomized IFM 99-04 protocol. Blood 2006; 107: 397–403.

    Article  CAS  Google Scholar 

  19. Facon T, Avet-Loiseau H, Guillerm G, Moreau P, Geneviève F, Zandecki M et al. Chromosome 13 abnormalities identified by FISH analysis and serum beta2-microglobulin produce a powerful myeloma staging system for patients receiving high-dose therapy. Blood 2001; 97: 1566–1571.

    Article  CAS  Google Scholar 

  20. Avet-Loiseau H, Attal M, Moreau P, Charbonnel C, Garban F, Hulin C et al. Genetic abnormalities and survival in multiple myeloma : the experience of the Intergroupe Francophone du Myélome. Blood 2007; 109: 3489–3495.

    Article  CAS  Google Scholar 

  21. Fonseca R, Stewart AK . Targeted therapeutics for multiple myeloma: the arrival of a risk-stratified approach. Mol Cancer Ther 2007; 6: 802–810.

    Article  CAS  Google Scholar 

  22. Shaughnessy JD, Zhan F, Burington BE, Huang Y, Colla S, Hanamura I et al. A validated gene expression model of high-risk multiple myeloma is defined by deregulated expression of genes mapping to chromosome 1. Blood 2007; 109: 2276–2284.

    Article  CAS  Google Scholar 

  23. Attal M, Harousseau JL, Stoppa AM, Sotto JJ, Fuzibet JG, Rossi JF et al. A prospective, randomized trial of autologous bone marrow transplantation and chemotherapy in multiple myeloma. N Engl J Med 1996; 335: 91–97.

    Article  CAS  Google Scholar 

  24. Child JA, Morgan GJ, Davies FE, Owen RG, Bell SE, Hawkins K et al. High-dose chemotherapy with hematopoietic stem-cell rescue for multiple myeloma. N Engl J Med 2003; 348: 1875–1883.

    Article  CAS  Google Scholar 

  25. Palumbo A, Bringhen S, Petrucci MT, Musto P, Rossini F, Nunzi M et al. Intermediate-dose melphalan improves survival of myeloma patients aged 50 to 70: results of a randomized controlled trial. Blood 2004; 104: 3052–3057.

    Article  CAS  Google Scholar 

  26. Sagaster V, Ludwig H, Kaufmann H, Odelga V, Zojer N, Ackermann J et al. Bortezomib in relapsed multiple myeloma: response rates and duration of response are independent of a chromosome 13q-deletion. Leukemia 2007; 21: 164–168.

    Article  CAS  Google Scholar 

  27. Bahlis NJ, Mansoor A, Lategan JC, Valentine K, Thaell T, Blahey W et al. Lenalidomide overcomes poor prognosis conferred by deletion of chromosome 13 and t(4;14) in multiple myeloma. Blood 2006; 108 (Suppl 1): 3557a.

    Google Scholar 

  28. Trudel S, Ely S, Farooqi Y, Affer M, Robbiani DF, Chesi M et al. Inhibition of fibroblast growth factor receptor 3 induces differentiation and apoptosis in t(4;14) myeloma. Blood 2004; 103: 3521–3528.

    Article  CAS  Google Scholar 

Download references

Acknowledgements

Contributors: P Moreau, JL Harousseau and H Avet-Loiseau designed the research and wrote the paper. P Moreau, M Attal and F Garban coordinated one of the clinical trials. H Avet-Loiseau performed the FISH analysis. All the other co-authors are members of the IFM group, and did participate in the design of the research and in patients' management. The authors indicated no potential conflicts of interest.

Author information

Authors and Affiliations

  1. Hematology Department, University Hospital, Nantes, France

    P Moreau & J L Harousseau

  2. Hematology Department, University Hospital, Toulouse, France

    M Attal

  3. Hematology Department, University Hospital, Grenoble, France

    F Garban

  4. Hematology Department, University Hospital, Nancy, France

    C Hulin

  5. Hematology Department, University Hospital, Lille, France

    T Facon & I Yakoub-Agha

  6. Hematology Department, University Hospital, Bordeaux, France

    G Marit

  7. Hematology Department, University Hospital Herriot, Lyon, France

    M Michallet

  8. Hematology Department, University Hospital, Bruxelles, Belgium

    C Doyen

  9. Hematology Department, University Hospital, Lausanne, Switzerland

    S Leyvraz

  10. Hematology Department, University Hospital, Marseille, France

    M Mohty

  11. Hematology Department, University Hospital, Dunkerque, France

    M Wetterwald

  12. Hematology Laboratory, University Hospital, Institut Curie, Paris, France

    C Mathiot

  13. Hematology Department, University Hospital, Dijon, France

    D Caillot

  14. Hematology Department, University Hospital, Brest, France

    C Berthou

  15. Hematology Department, University Hospital, Tours, France

    L Benboubker

  16. Hematology Department, University Hospital Saint-Antoine, Paris, France

    L Garderet

  17. Hematology Department, University Hospital, Clermont-Ferrand, France

    C Chaleteix

  18. Hematology Department, University Hospital Lyon Sud, Lyon, France

    C Traullé

  19. Hematology Department, University Hospital, Nice, France

    J G Fuzibet

  20. Hematology Department, University Hospital, Saint-Etienne, France

    J Jaubert

  21. Hematology Department, University Hospital Pontchaillou, Rennes, France

    T Lamy

  22. Hematology Department, University Hospital Bobigny, Paris, France

    P Casassus

  23. Hematology Department, University Hospital, Angers, France

    M Dib

  24. Hematology Department, University Hospital, Reims, France

    B Kolb

  25. Hematology Department, University Hospital, Metz, France

    V Dorvaux

  26. Hematology Department, University Hospital Rennes Sud, Rennes, France

    B Grosbois

  27. Hematology Laboratory, University Hospital, Nantes, France

    H Avet-Loiseau

Authors
  1. P Moreau
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. M Attal
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. F Garban
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. C Hulin
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. T Facon
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. G Marit
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. M Michallet
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. C Doyen
    View author publications

    You can also search for this author in PubMed Google Scholar

  9. S Leyvraz
    View author publications

    You can also search for this author in PubMed Google Scholar

  10. M Mohty
    View author publications

    You can also search for this author in PubMed Google Scholar

  11. M Wetterwald
    View author publications

    You can also search for this author in PubMed Google Scholar

  12. C Mathiot
    View author publications

    You can also search for this author in PubMed Google Scholar

  13. D Caillot
    View author publications

    You can also search for this author in PubMed Google Scholar

  14. C Berthou
    View author publications

    You can also search for this author in PubMed Google Scholar

  15. L Benboubker
    View author publications

    You can also search for this author in PubMed Google Scholar

  16. L Garderet
    View author publications

    You can also search for this author in PubMed Google Scholar

  17. C Chaleteix
    View author publications

    You can also search for this author in PubMed Google Scholar

  18. C Traullé
    View author publications

    You can also search for this author in PubMed Google Scholar

  19. J G Fuzibet
    View author publications

    You can also search for this author in PubMed Google Scholar

  20. J Jaubert
    View author publications

    You can also search for this author in PubMed Google Scholar

  21. T Lamy
    View author publications

    You can also search for this author in PubMed Google Scholar

  22. P Casassus
    View author publications

    You can also search for this author in PubMed Google Scholar

  23. M Dib
    View author publications

    You can also search for this author in PubMed Google Scholar

  24. B Kolb
    View author publications

    You can also search for this author in PubMed Google Scholar

  25. V Dorvaux
    View author publications

    You can also search for this author in PubMed Google Scholar

  26. B Grosbois
    View author publications

    You can also search for this author in PubMed Google Scholar

  27. I Yakoub-Agha
    View author publications

    You can also search for this author in PubMed Google Scholar

  28. J L Harousseau
    View author publications

    You can also search for this author in PubMed Google Scholar

  29. H Avet-Loiseau
    View author publications

    You can also search for this author in PubMed Google Scholar

Consortia

on behalf of the SAKK and IFM group

Corresponding author

Correspondence to H Avet-Loiseau.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Moreau, P., Attal, M., Garban, F. et al. Heterogeneity of t(4;14) in multiple myeloma. Long-term follow-up of 100 cases treated with tandem transplantation in IFM99 trials. Leukemia 21, 2020–2024 (2007). https://doi.org/10.1038/sj.leu.2404832

Download citation

  • Received:

  • Revised:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/sj.leu.2404832

Keywords

This article is cited by

Search

Advanced search

Quick links